SlideShare ist ein Scribd-Unternehmen logo
1 von 28
Ambiance Ventures USA Focus on Brazil & Latin America
Ambiance Ventures  USA Ambiance Ventures USA ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Ambiance Ventures  USA ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Ambiance Ventures  USA
Ambiance Ventures  USA FOCUS: Opportunities for GENERICS IN BRAZIL, Latin America: An Overview
Ambiance Ventures  USA ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Environment
Ambiance Ventures  USA ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Environment
Ambiance Ventures  USA ,[object Object],[object Object],[object Object],[object Object]
Ambiance Ventures  USA Local Situation: There are approx. 100 producers with registrations for generic medicines in Brazil.  Medley and EMS are the leaders (65% combined market share). Eurofarma and Aché (15% combined market share) Problem with sub-bioequivalent products of smaller manufacturers
Ambiance Ventures  USA ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Ambiance Ventures  USA THE OPPORTUNITY IN BRAZIL  & LATIN AMERICA: … ..Right Time, Right Market! (with the Right approach!) Nearly $140 billion of branded products coming off patent by 2016  President  of Brazil:  The Hon. Luiz Inácio Lula da Silva
Ambiance Ventures  USA Blockbusters in Brazil:  A number of products are due to lose their patent protection between 2007 and 2012, bringing market opportunities worth US$307.2 million to the generics sector in Brazil  In March 2007, ANVISA authorized the registration of generic  alternatives to oral contraceptives and endogenous hormones:  Valued at US$481 million in 2006 and generic producers are expected to account for 60% by 2012
Ambiance Ventures  USA HIV Generics: Market Potential in Brazil Brazil had an estimated HIV population of 620,000 adults and children , with 14,000 individuals dying from AIDS each year. President Lula da Silva has issued a 'compulsory license' that bypasses the patent on the HIV drug Sustiva® (Efavirenz), marketed by Merck & Co.  as Stocrin® in developing countries Brazil's will therefore bypass Merck's patent  Sustiva® (efavirenz) in order to manufacture it as a lower-priced generic.  This will increase therapy-access for many HIV/AIDS patients.  The Brazilian Govt.  is seeking lower prices to limit the cost of its program providing free treatment to all people in Brazil infected with HIV. Brazil can issue ‘Compulsory Licences’ and allow local generic production of imported Antiretrovirals. Thus far, it has negotiated drug price reductions and encouraged local production under license. ……a great business opportunity for local manufacturers. Brazil will save $30 million this year by purchasing  generic  Efavirenz  and  will  cut $237 million from its HIV/AIDS drug bill through 2012 ireuld expire
Ambiance Ventures  USA ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Ambiance Ventures  USA ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Ambiance Ventures  USA ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Ambiance Ventures  USA ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Ambiance Ventures  USA
Ambiance Ventures  USA ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Ambiance Ventures  USA
Ambiance Ventures  USA ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Ambiance Ventures  USA ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Ambiance Ventures  USA OUR SPECIALTY: Leverage low cost contract manufacture at our facilities! NEUTRAL LABEL, PRIVATE LABEL CONTRACT MANUFACTURE: Generics, Cosmetics, Diagnostics Custom Packaging  – For Re-distribution Neutral (‘generic drug’) labeling   per Ministerio da Saude requirements In Portuguese / English / Spanish (for re-export) Private labeling  with your own Brand Name, Company Identity,  Compliant with regulations – Pharmacies, HMOs, Export,  Secondary Distribution
Ambiance Ventures  USA A Division of Ambiance Ventures  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Ambiance Ventures  USA ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Ambiance Ventures  USA ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Ambiance Ventures  USA A Division of Ambiance Ventures  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Ambiance Ventures  USA Contact: Jay Nadkarni Ambiance Ventures, USA Swiftwater, Pennsylvania 18370  (USA) Tel: 570/ 460-1804;  Fax: 570/ 688-0975 [email_address] Contact: Valerian Lobo LOB International, India G-6 Khira Industrial Estates, B.M. Bhargava Rd. Santa Cruz (W), Mumbai 400 054 (INDIA) Tel: 9122- 2661-5006, 9122-2661-6008 [email_address]

Weitere ähnliche Inhalte

Was ist angesagt?

Shivai Gupta - POSTER
Shivai Gupta - POSTERShivai Gupta - POSTER
Shivai Gupta - POSTER
Shivai Gupta
 
p-186 Orphan drugs and Rare Diseases
p-186 Orphan drugs and Rare Diseasesp-186 Orphan drugs and Rare Diseases
p-186 Orphan drugs and Rare Diseases
Kiran Bains
 
Market Access in Latin America Leaders Forum - Agenda
Market Access in Latin America Leaders Forum - AgendaMarket Access in Latin America Leaders Forum - Agenda
Market Access in Latin America Leaders Forum - Agenda
Andrea Basagoitia. Ph.D
 
Building Biotechnology in India
Building Biotechnology in IndiaBuilding Biotechnology in India
Building Biotechnology in India
thinkBiotech
 

Was ist angesagt? (18)

Pfizer
PfizerPfizer
Pfizer
 
Use of testimonials and endorsements in prescription drug advertisements
Use of testimonials and endorsements in prescription drug advertisementsUse of testimonials and endorsements in prescription drug advertisements
Use of testimonials and endorsements in prescription drug advertisements
 
Shivai Gupta - POSTER
Shivai Gupta - POSTERShivai Gupta - POSTER
Shivai Gupta - POSTER
 
Counterfeit drugs presentation to Pharmacy-3 students in South Dakota
Counterfeit drugs presentation to Pharmacy-3 students in South DakotaCounterfeit drugs presentation to Pharmacy-3 students in South Dakota
Counterfeit drugs presentation to Pharmacy-3 students in South Dakota
 
Orphan Drug 101
Orphan Drug 101Orphan Drug 101
Orphan Drug 101
 
p-186 Orphan drugs and Rare Diseases
p-186 Orphan drugs and Rare Diseasesp-186 Orphan drugs and Rare Diseases
p-186 Orphan drugs and Rare Diseases
 
Market Access in Latin America Leaders Forum - Agenda
Market Access in Latin America Leaders Forum - AgendaMarket Access in Latin America Leaders Forum - Agenda
Market Access in Latin America Leaders Forum - Agenda
 
Orphan Drug Report
Orphan Drug ReportOrphan Drug Report
Orphan Drug Report
 
89224053 study-case-j-j
89224053 study-case-j-j89224053 study-case-j-j
89224053 study-case-j-j
 
Pharmaceutical globalization: Where are drugs invented?
Pharmaceutical globalization: Where are drugs invented?Pharmaceutical globalization: Where are drugs invented?
Pharmaceutical globalization: Where are drugs invented?
 
ORPHAN DRUGS- ACTS, PAST AND CURRENT SCENARIO, WITH UPCOMING DRUGS
ORPHAN DRUGS- ACTS, PAST AND CURRENT SCENARIO, WITH UPCOMING DRUGSORPHAN DRUGS- ACTS, PAST AND CURRENT SCENARIO, WITH UPCOMING DRUGS
ORPHAN DRUGS- ACTS, PAST AND CURRENT SCENARIO, WITH UPCOMING DRUGS
 
Using patent information to track globalization
Using patent information to track globalizationUsing patent information to track globalization
Using patent information to track globalization
 
LATAMMA16_m
LATAMMA16_mLATAMMA16_m
LATAMMA16_m
 
Building Biotechnology in India
Building Biotechnology in IndiaBuilding Biotechnology in India
Building Biotechnology in India
 
Merck: Global Health and Access to Medicines
Merck: Global Health and Access to  MedicinesMerck: Global Health and Access to  Medicines
Merck: Global Health and Access to Medicines
 
Orphan drugs: why the hype?
Orphan drugs: why the hype?Orphan drugs: why the hype?
Orphan drugs: why the hype?
 
Health Canada Cracks Down on Illegal Growers, Again!
Health Canada Cracks Down on Illegal Growers, Again!Health Canada Cracks Down on Illegal Growers, Again!
Health Canada Cracks Down on Illegal Growers, Again!
 
BioEntrepreneurship: Intellectual Property: What Do Investors Look For?
BioEntrepreneurship: Intellectual Property: What Do Investors Look For?BioEntrepreneurship: Intellectual Property: What Do Investors Look For?
BioEntrepreneurship: Intellectual Property: What Do Investors Look For?
 

Ähnlich wie Focus On Brazil 1.7

Focus On Brazil 1.6
Focus On Brazil 1.6Focus On Brazil 1.6
Focus On Brazil 1.6
Jay Nadkarni
 
The new war on pharmaceutical drugs
The new war on pharmaceutical drugsThe new war on pharmaceutical drugs
The new war on pharmaceutical drugs
Duygu Can
 
Newtech advant-business-plan9
Newtech advant-business-plan9Newtech advant-business-plan9
Newtech advant-business-plan9
Yousaf Khan
 
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
Pinky Fadullon
 
Biotechnology 1
Biotechnology 1Biotechnology 1
Biotechnology 1
sokraturk
 
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
MedicineAndHealthUSA
 
White paper stopping counterfeit pharmaceuticals 0309
White  paper stopping counterfeit pharmaceuticals 0309White  paper stopping counterfeit pharmaceuticals 0309
White paper stopping counterfeit pharmaceuticals 0309
NEW Momentum
 
Aiden hollis hif presentation berkeley
Aiden hollis   hif presentation berkeleyAiden hollis   hif presentation berkeley
Aiden hollis hif presentation berkeley
Open Science Summit
 

Ähnlich wie Focus On Brazil 1.7 (20)

Focus On Brazil 1.6
Focus On Brazil 1.6Focus On Brazil 1.6
Focus On Brazil 1.6
 
Pfizer Inc
Pfizer IncPfizer Inc
Pfizer Inc
 
PMRG 2008 Presentation
PMRG 2008 PresentationPMRG 2008 Presentation
PMRG 2008 Presentation
 
The new war on pharmaceutical drugs
The new war on pharmaceutical drugsThe new war on pharmaceutical drugs
The new war on pharmaceutical drugs
 
NOVEMBER 2021 EDITION OF NUTRIFYTODAY MAGAZINE
NOVEMBER 2021 EDITION OF NUTRIFYTODAY MAGAZINENOVEMBER 2021 EDITION OF NUTRIFYTODAY MAGAZINE
NOVEMBER 2021 EDITION OF NUTRIFYTODAY MAGAZINE
 
The Future of the Pharmaceutical Industry in Spain
The Future of the Pharmaceutical Industry in SpainThe Future of the Pharmaceutical Industry in Spain
The Future of the Pharmaceutical Industry in Spain
 
Newtech advant-business-plan9
Newtech advant-business-plan9Newtech advant-business-plan9
Newtech advant-business-plan9
 
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
 
Differentiation strategies for the generic industrry
Differentiation strategies for the generic industrryDifferentiation strategies for the generic industrry
Differentiation strategies for the generic industrry
 
johnson n johnson
johnson n johnsonjohnson n johnson
johnson n johnson
 
Biotechnology 1
Biotechnology 1Biotechnology 1
Biotechnology 1
 
What is a biosimilar? All you need to know about the current biologics and bi...
What is a biosimilar? All you need to know about the current biologics and bi...What is a biosimilar? All you need to know about the current biologics and bi...
What is a biosimilar? All you need to know about the current biologics and bi...
 
Generics and the Animal Health Industry
Generics and the Animal Health IndustryGenerics and the Animal Health Industry
Generics and the Animal Health Industry
 
Anandapharm summary 05092020 mw (v12)
Anandapharm summary 05092020 mw (v12)Anandapharm summary 05092020 mw (v12)
Anandapharm summary 05092020 mw (v12)
 
Marketing Presentation For 2011 MBA Program
Marketing Presentation For 2011 MBA ProgramMarketing Presentation For 2011 MBA Program
Marketing Presentation For 2011 MBA Program
 
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
 
BioEntrepreneurship: The Business of Biotech
BioEntrepreneurship: The Business of BiotechBioEntrepreneurship: The Business of Biotech
BioEntrepreneurship: The Business of Biotech
 
2015 Pharmaceutical Sales Rep Experience
2015 Pharmaceutical Sales Rep Experience 2015 Pharmaceutical Sales Rep Experience
2015 Pharmaceutical Sales Rep Experience
 
White paper stopping counterfeit pharmaceuticals 0309
White  paper stopping counterfeit pharmaceuticals 0309White  paper stopping counterfeit pharmaceuticals 0309
White paper stopping counterfeit pharmaceuticals 0309
 
Aiden hollis hif presentation berkeley
Aiden hollis   hif presentation berkeleyAiden hollis   hif presentation berkeley
Aiden hollis hif presentation berkeley
 

Mehr von Jay Nadkarni (9)

Ambiance Ventures - Access to Emerging Markets
Ambiance Ventures - Access to Emerging MarketsAmbiance Ventures - Access to Emerging Markets
Ambiance Ventures - Access to Emerging Markets
 
Pharmagesic local presentation linked in 050813
Pharmagesic local presentation linked in 050813Pharmagesic local presentation linked in 050813
Pharmagesic local presentation linked in 050813
 
Global Mktg Presentation 3.0
Global Mktg Presentation 3.0Global Mktg Presentation 3.0
Global Mktg Presentation 3.0
 
Global Mktg Presentation 3.0
Global Mktg Presentation 3.0Global Mktg Presentation 3.0
Global Mktg Presentation 3.0
 
Global Mktg Presentation 3.0
Global Mktg Presentation 3.0Global Mktg Presentation 3.0
Global Mktg Presentation 3.0
 
Global Mktg Presentation 3.0
Global Mktg Presentation 3.0Global Mktg Presentation 3.0
Global Mktg Presentation 3.0
 
Global Mktg Presentation 3.0
Global Mktg Presentation 3.0Global Mktg Presentation 3.0
Global Mktg Presentation 3.0
 
Global Mktg Presentation 3.0
Global Mktg Presentation 3.0Global Mktg Presentation 3.0
Global Mktg Presentation 3.0
 
Focus On Brazil 1.8
Focus On Brazil 1.8Focus On Brazil 1.8
Focus On Brazil 1.8
 

Focus On Brazil 1.7

  • 1. Ambiance Ventures USA Focus on Brazil & Latin America
  • 2.
  • 3.
  • 5. Ambiance Ventures USA FOCUS: Opportunities for GENERICS IN BRAZIL, Latin America: An Overview
  • 6.
  • 7.
  • 8.
  • 9. Ambiance Ventures USA Local Situation: There are approx. 100 producers with registrations for generic medicines in Brazil. Medley and EMS are the leaders (65% combined market share). Eurofarma and Aché (15% combined market share) Problem with sub-bioequivalent products of smaller manufacturers
  • 10.
  • 11. Ambiance Ventures USA THE OPPORTUNITY IN BRAZIL & LATIN AMERICA: … ..Right Time, Right Market! (with the Right approach!) Nearly $140 billion of branded products coming off patent by 2016 President of Brazil: The Hon. Luiz Inácio Lula da Silva
  • 12. Ambiance Ventures USA Blockbusters in Brazil: A number of products are due to lose their patent protection between 2007 and 2012, bringing market opportunities worth US$307.2 million to the generics sector in Brazil In March 2007, ANVISA authorized the registration of generic alternatives to oral contraceptives and endogenous hormones: Valued at US$481 million in 2006 and generic producers are expected to account for 60% by 2012
  • 13. Ambiance Ventures USA HIV Generics: Market Potential in Brazil Brazil had an estimated HIV population of 620,000 adults and children , with 14,000 individuals dying from AIDS each year. President Lula da Silva has issued a 'compulsory license' that bypasses the patent on the HIV drug Sustiva® (Efavirenz), marketed by Merck & Co. as Stocrin® in developing countries Brazil's will therefore bypass Merck's patent Sustiva® (efavirenz) in order to manufacture it as a lower-priced generic. This will increase therapy-access for many HIV/AIDS patients. The Brazilian Govt. is seeking lower prices to limit the cost of its program providing free treatment to all people in Brazil infected with HIV. Brazil can issue ‘Compulsory Licences’ and allow local generic production of imported Antiretrovirals. Thus far, it has negotiated drug price reductions and encouraged local production under license. ……a great business opportunity for local manufacturers. Brazil will save $30 million this year by purchasing generic Efavirenz and will cut $237 million from its HIV/AIDS drug bill through 2012 ireuld expire
  • 14.
  • 15.
  • 16.
  • 17.
  • 19.
  • 21.
  • 22.
  • 23. Ambiance Ventures USA OUR SPECIALTY: Leverage low cost contract manufacture at our facilities! NEUTRAL LABEL, PRIVATE LABEL CONTRACT MANUFACTURE: Generics, Cosmetics, Diagnostics Custom Packaging – For Re-distribution Neutral (‘generic drug’) labeling per Ministerio da Saude requirements In Portuguese / English / Spanish (for re-export) Private labeling with your own Brand Name, Company Identity, Compliant with regulations – Pharmacies, HMOs, Export, Secondary Distribution
  • 24.
  • 25.
  • 26.
  • 27.
  • 28. Ambiance Ventures USA Contact: Jay Nadkarni Ambiance Ventures, USA Swiftwater, Pennsylvania 18370 (USA) Tel: 570/ 460-1804; Fax: 570/ 688-0975 [email_address] Contact: Valerian Lobo LOB International, India G-6 Khira Industrial Estates, B.M. Bhargava Rd. Santa Cruz (W), Mumbai 400 054 (INDIA) Tel: 9122- 2661-5006, 9122-2661-6008 [email_address]

Hinweis der Redaktion

  1. Spain